Arecoline

Interesting as pharmacology, dangerous as a habit. The muscarinic partial agonism is real and was tested in Alzheimer's disease with marginal results, but the compound reaches most of its users as betel quid, which the IARC classifies as a Group 1 human carcinogen. Nothing in the cognitive literature comes close to offsetting that, and an entry that reads this compound as a nootropic is reading it wrong.

The dominant hazard here is not cholinergic. Betel quid, with or without tobacco, is classified by the IARC as a Group 1 human carcinogen, and its use carries elevated risk of oral potentially malignant disorders and of cancers of the oral cavity and pharynx across an estimated 600 million users worldwide ^[4]. Arecoline itself was evaluated for the first time in IARC Monographs Volume 128 and placed in Group 2B, possibly carcinogenic to humans, on the strength of mechanistic evidence ^[3]. Two mechanisms are documented.

Arecoline pushes buccal mucosal fibroblasts toward a myofibroblast phenotype through a Snail and interleukin 6 feedback loop, which is the pathway behind oral submucous fibrosis, the precancerous condition that precedes many of these cancers ^[5]. Its oxidative metabolite arecoline N-oxide is more cytotoxic, genotoxic and mutagenic than the parent, generating reactive oxygen species through mitochondrial cytochrome P450 metabolism ^[6]. On top of that sit the ordinary cholinergic effects, heavy salivation above all, plus withdrawal-like anxiety on discontinuation in animal models ^[11]. Long-term controlled human data on isolated arecoline, as opposed to whole betel quid, have not been generated.

Arecoline is the principal alkaloid of the seed of Areca catechu, the areca palm of South and Southeast Asia, and the practice of chewing that seed as betel quid is ancient and still enormous in scale. Its modern research career was as a cholinergic probe. The Laboratory of Neurosciences at the US National Institute on Aging ran intravenous arecoline infusions in mild to moderate Alzheimer's disease through the late 1980s and early 1990s, working out its pharmacokinetics and titrating a per-patient optimal dose against memory testing; effects were small, varied fourfold between patients, and the plasma half-life was measured in minutes. No oral programme followed. Attention since has shifted almost entirely to areca cessation and to using the arecoline scaffold to build selective nicotinic partial agonists that leave the muscarinic activity behind.

Among pharmacologists arecoline is a standard reference partial agonist and a textbook case of a natural product carrying both muscarinic and nicotinic activity. Among dental and cancer researchers it is a carcinogenesis problem with several hundred million exposed people attached to it. The occasional framing of arecoline as a cognitive enhancer has no serious constituency and sits badly against the oncology literature.